279 related articles for article (PubMed ID: 23806121)
1. Polymyxin derivatives: a patent evaluation (WO2012168820).
Wu H; Teng P; Niu Y; Li Q; Cai J
Expert Opin Ther Pat; 2013 Aug; 23(8):1075-81. PubMed ID: 23806121
[TBL] [Abstract][Full Text] [Related]
2. Polymyxins and their novel derivatives.
Vaara M
Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
[TBL] [Abstract][Full Text] [Related]
3. Polymyxin B nonapeptide potentiates the eradication of Gram-negative bacterial persisters.
Kim SJ; Jo J; Kim J; Ko KS; Lee W
Microbiol Spectr; 2024 Apr; 12(4):e0368723. PubMed ID: 38391225
[TBL] [Abstract][Full Text] [Related]
4. Development of dilipid polymyxins: Investigation on the effect of hydrophobicity through its fatty acyl component.
Domalaon R; Berry L; Tays Q; Zhanel GG; Schweizer F
Bioorg Chem; 2018 Oct; 80():639-648. PubMed ID: 30053708
[TBL] [Abstract][Full Text] [Related]
5. Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.
Brown P; Dawson MJ
J Antibiot (Tokyo); 2017 Apr; 70(4):386-394. PubMed ID: 28074057
[TBL] [Abstract][Full Text] [Related]
6. Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics.
Vaara M
Molecules; 2019 Jan; 24(2):. PubMed ID: 30641878
[TBL] [Abstract][Full Text] [Related]
7. Teaching 'old' polymyxins new tricks: new-generation lipopeptides targeting gram-negative 'superbugs'.
Velkov T; Roberts KD; Nation RL; Wang J; Thompson PE; Li J
ACS Chem Biol; 2014 May; 9(5):1172-7. PubMed ID: 24601489
[TBL] [Abstract][Full Text] [Related]
8. Activity of polymyxin B and the novel polymyxin analogue CB-182,804 against contemporary Gram-negative pathogens in New York City.
Quale J; Shah N; Kelly P; Babu E; Backer M; Rosas-Garcia G; Salamera J; George A; Bratu S; Landman D
Microb Drug Resist; 2012 Apr; 18(2):132-6. PubMed ID: 22196342
[TBL] [Abstract][Full Text] [Related]
9. Novel polymyxin derivatives are less cytotoxic than polymyxin B to renal proximal tubular cells.
Mingeot-Leclercq MP; Tulkens PM; Denamur S; Vaara T; Vaara M
Peptides; 2012 Jun; 35(2):248-52. PubMed ID: 22504013
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections.
Magee TV; Brown MF; Starr JT; Ackley DC; Abramite JA; Aubrecht J; Butler A; Crandon JL; Dib-Hajj F; Flanagan ME; Granskog K; Hardink JR; Huband MD; Irvine R; Kuhn M; Leach KL; Li B; Lin J; Luke DR; MacVane SH; Miller AA; McCurdy S; McKim JM; Nicolau DP; Nguyen TT; Noe MC; O'Donnell JP; Seibel SB; Shen Y; Stepan AF; Tomaras AP; Wilga PC; Zhang L; Xu J; Chen JM
J Med Chem; 2013 Jun; 56(12):5079-93. PubMed ID: 23735048
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
[TBL] [Abstract][Full Text] [Related]
12. Structure--activity relationships of polymyxin antibiotics.
Velkov T; Thompson PE; Nation RL; Li J
J Med Chem; 2010 Mar; 53(5):1898-916. PubMed ID: 19874036
[No Abstract] [Full Text] [Related]
13. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
Gales AC; Jones RN; Sader HS
J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
[TBL] [Abstract][Full Text] [Related]
14. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
Zavascki AP; Goldani LZ; Li J; Nation RL
J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
Vaara M; Sader HS; Rhomberg PR; Jones RN; Vaara T
J Antimicrob Chemother; 2013 Mar; 68(3):636-9. PubMed ID: 23134658
[TBL] [Abstract][Full Text] [Related]
16. Can octapeptin antibiotics combat extensively drug-resistant (XDR) bacteria?
Blaskovich MAT; Pitt ME; Elliott AG; Cooper MA
Expert Rev Anti Infect Ther; 2018 Jun; 16(6):485-499. PubMed ID: 29848132
[TBL] [Abstract][Full Text] [Related]
17. Clinical translation of polymyxin-based combination therapy: Facts, challenges and future opportunities.
Zhang X; Guo F; Shao H; Zheng X
J Infect; 2017 Feb; 74(2):118-130. PubMed ID: 27998750
[TBL] [Abstract][Full Text] [Related]
18. History, Chemistry and Antibacterial Spectrum.
Velkov T; Thompson PE; Azad MAK; Roberts KD; Bergen PJ
Adv Exp Med Biol; 2019; 1145():15-36. PubMed ID: 31364069
[TBL] [Abstract][Full Text] [Related]
19. Emergence of polymyxin resistance in Gram-negative bacteria.
Olaitan AO; Li J
Int J Antimicrob Agents; 2016 Dec; 48(6):581-582. PubMed ID: 27939183
[No Abstract] [Full Text] [Related]
20. Neopeptide antibiotics that function as opsonins and membrane-permeabilizing agents for gram-negative bacteria.
Tsubery H; Yaakov H; Cohen S; Giterman T; Matityahou A; Fridkin M; Ofek I
Antimicrob Agents Chemother; 2005 Aug; 49(8):3122-8. PubMed ID: 16048913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
